NCT04524871 - A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Biotech Hunter

Enrollment

518

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Liver Cancers

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

DRUG

Bevacizumab 15 mg/kg

Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

DRUG

Tiragolumab

Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

DRUG

Tocilizumab

Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.

DRUG

TPST-1120

TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.

DRUG

Tobemstomig 2100 mg

Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.

DRUG

Bevacizumab 10 mg/kg

Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.

DRUG

Tobemstomig 600 mg

Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

DRUG

Tobemstomig 1200 mg

Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.

DRUG

ADG126

ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).

DRUG

IO-108 1800 mg

IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.

DRUG

NKT2152

NKT2152 will be administered by mouth.

DRUG

IO-108 1200 mg

IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.

Trial Locations (33)

1023

RECRUITING

Auckland City Hospital, Auckland

5505

RECRUITING

Asan Medical Center, Seoul

10002

RECRUITING

National Taiwan University Hospital, Taipei

13496

ACTIVE_NOT_RECRUITING

CHA Bundang Medical Center, Gyeonggi-do

20007

RECRUITING

Georgetown University Medical Center, Washington D.C.

21079

RECRUITING

Centre Georges Francois Leclerc, Dijon

35042

RECRUITING

Centre Eugène Marquis, Rennes

37203

COMPLETED

Sarah Cannon Research Institute / Tennessee Oncology, Nashville

49100

RECRUITING

Rabin Medical Center-Beilinson Campus, Petah Tikva

64239

RECRUITING

Sourasky Medical Centre, Tel Aviv

70457

RECRUITING

National Cheng Kung University Hospital, Tainan City

75235

RECRUITING

Parkland Health & Hospital System, Dallas

75390

RECRUITING

The University of Texas Southwestern Medical Center at Dallas, Dallas

80045

RECRUITING

Cherry Creek Medical Center, Aurora

RECRUITING

UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital, Aurora

RECRUITING

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

90404

RECRUITING

UCLA Center for East, Santa Monica

91010

RECRUITING

City of Hope, Duarte

92093

RECRUITING

University of California San Diego, La Jolla

92627

RECRUITING

UC Irvine Medical Center, Costa Mesa

92868

RECRUITING

UC Irvine Medical Center, Orange

94115

RECRUITING

University of California San Francisco Cancer Center, San Francisco

94800

RECRUITING

Gustave Roussy, Villejuif

97239

RECRUITING

Oregon Health & Science University, Portland

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200032

COMPLETED

Zhongshan Hospital Fudan University, Shanghai

3109601

RECRUITING

Rambam Medical Center, Haifa

06510

RECRUITING

Smilow Cancer Hospital at Yale New Haven, New Haven

40536-7001

RECRUITING

University of Kentucky - Markey Cancer Center, Lexington

Unknown

RECRUITING

CHU Hôpitaux de Marseille, Marseille

RECRUITING

Hadassah University Medical Center, Jerusalem

03080

WITHDRAWN

Seoul National University Hospital, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul